Here's Why You Should Hold OPK Stock in Your Portfolio for Now

Core Viewpoint - OPKO Health, Inc. is positioned for growth driven by RAYALDEE's performance and strategic partnerships, despite facing competition and reliance on RAYALDEE [1][8] Company Overview - OPKO Health has a market capitalization of $903.3 million and anticipates a 10% growth for 2026, maintaining strong performance [2] - The company has surpassed earnings estimates in two of the last four quarters, with an average beat of 41.97% [2] Factors Favoring OPK Stock - Strategic transformation through the divestiture of oncology diagnostics has streamlined operations, resulting in a nearly 29% workforce reduction and improved margins [3][4] - The focus on core clinical labs and the 4Kscore franchise is expected to lead to positive operating income and cash flow by 2026 [4] - ModeX has developed into a multi-asset clinical-stage platform with collaborations, including a partnership with Regeneron that could exceed $1 billion in milestones and royalties [5][6] - Increasing revenues from partnerships, such as a record $12.5 million gross profit share from Pfizer's NGENLA, are diversifying OPKO's income base [9][10] Challenges Facing OPK Stock - OPKO reported a 19% year-over-year revenue decline due to asset divestitures and restructuring, which poses execution risks as the company rebuilds from a smaller base [11][12] - Continued operating losses were reported, with an operating loss of $38.3 million in the fourth quarter, and expenses for 2026 expected to exceed revenues significantly [13] - A negative estimate revision trend for 2026 has emerged, with the loss per share estimate widening to 27 cents, and a projected revenue decline of 12.9% year-over-year [14]